{
    "patient": {
        "Name": "Cameron Moore",
        "DateOfBirth": "1986-04-08",
        "Sex": "Female",
        "Diagnosis": "Invasive ductal carcinoma",
        "BodyPart": "Breast",
        "Physician": "Dr. Troy Sosa",
        "TreatingInstitution": "Cline Inc"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Breast",
            "CollectedDate": "2023-09-07",
            "ReceivedDate": "2023-09-08",
            "TumorPercentage": "93%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-09-12",
            "ReceivedDate": "2023-09-12"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "B2M",
                "DNA Alteration": "c.2T>G",
                "GeneMutation": "p.M1R Stopgain-LOF",
                "VariantAlleleFraction": "17.61%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "HBB",
                "DNA Alteration": "c.364G>C",
                "GeneMutation": "p.E7K Spliceregionvariant-LOF",
                "VariantAlleleFraction": "27.4%"
            },
            {
                "Gene": "NOTCH1",
                "DNA Alteration": "c.7398del",
                "GeneMutation": "p.E122K Spliceregionvariant-GOF",
                "VariantAlleleFraction": "23.28%"
            },
            {
                "Gene": "CCND3",
                "DNA Alteration": "c.766_776del11",
                "GeneMutation": "p.E27K Spliceregionvariant-GOF",
                "VariantAlleleFraction": "24.74%"
            },
            {
                "Gene": "HDAC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R256fs*64 Frameshift-LOF",
                "VariantAlleleFraction": "5.19%"
            },
            {
                "Gene": "ERCC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.E7V Stopgain-LOF",
                "VariantAlleleFraction": "9.61%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "EZH2",
            "PTCH1",
            "SRSF2",
            "STAT5B"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "29 m/Mb",
            "Tmbpercentile": "46%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "EZH2",
                "DNA Alteration": "c.1936T>A",
                "GeneMutation": "p.Y646H Spliceregionvariant-LOF",
                "VariantAlleleFraction": "3.67%"
            },
            {
                "Gene": "MAPK1",
                "DNA Alteration": "c.964G>A",
                "GeneMutation": "p.E322K Frameshift-LOF",
                "VariantAlleleFraction": "8.93%"
            },
            {
                "Gene": "SDHD",
                "DNA Alteration": "c.34G>A",
                "GeneMutation": "p.G12S Frameshift-LOF",
                "VariantAlleleFraction": "10.67%"
            },
            {
                "Gene": "BTK",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.C481X Nonsense-GOF",
                "VariantAlleleFraction": "7.56%"
            },
            {
                "Gene": "EZH2",
                "DNA Alteration": "c.1937A>G",
                "GeneMutation": "p.Y646C Nonsense-GOF",
                "VariantAlleleFraction": "6.35%"
            },
            {
                "Gene": "NTRK1",
                "DNA Alteration": "c.1792C>T",
                "GeneMutation": "p.G607V Nonsense-GOF",
                "VariantAlleleFraction": "4.79%"
            }
        ],
        "Germline": [
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.134C>T",
                "GeneMutation": "p.D32N Missensevariant(exon2)-GOF",
                "Condition": "care"
            }
        ]
    },
    "low coverage regions": [
        "U2AF1",
        "IDH2"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "B2M",
                "DNA Alteration": "c.2T>G",
                "GeneMutation": "p.M1R Stopgain-LOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "17.61%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "HBB",
                "DNA Alteration": "c.364G>C",
                "GeneMutation": "p.E7K Spliceregionvariant-LOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "27.4%"
            },
            {
                "Gene": "NOTCH1",
                "DNA Alteration": "c.7398del",
                "GeneMutation": "p.E122K Spliceregionvariant-GOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "23.28%"
            },
            {
                "Gene": "CCND3",
                "DNA Alteration": "c.766_776del11",
                "GeneMutation": "p.E27K Spliceregionvariant-GOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "24.74%"
            },
            {
                "Gene": "HDAC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R256fs*64 Frameshift-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "5.19%"
            },
            {
                "Gene": "ERCC2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.E7V Stopgain-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "9.61%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-08-31"
    },
    "other": {
        "ReportId": "7333",
        "ReportDate": "2023-09-15",
        "SignedBy": "Troy Sosa",
        "Supervisor": "Dr. Matthew Barton"
    }
}